Lymphokine activated killer (LAK) cell activity against renal cancer cell lines was assessed in vitro using a crystal violet assay. A standard 4-h 51chromium release assay and a 48-h crystal violet assay showed that both natural killer-susceptible (NC65) and-resistant (ACHN) renal cancer cell lines were sensitive to LAK cells which had been generated by a 3-day incubation of peripheral blood mononuclear cells (PBMC) with recombinant interleukin 2 (rIL-2). Optimal LAK activity was generated by a 5-day culture of PBMC with 1 U rIL-2/ml. LAK activity was enhanced by the presence of IL-2 in the crystal violet assay system, while it was suppressed by fresh autologous serum. The suppressive effect was found in serum from both normal donors and patients with metastatic renal cell carcinoma, suggesting that non-specific suppressive factor(s) affecting LAK cell activity were present in human sera.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Balch CM, Itoh K and Tilden AB (1985) Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 98:151–157
Böyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest [Suppl] 21:77–89
Eggermont AMM and Sugarbaker PH (1987) Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy. Cell Immunol 107:384–394
Ettinghausen SE and Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46:2784–2792
Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841
Hoehn W and Schroeder FH (1978) Renal cell carcinoma: two new cell lines and a serially transplantable nude mouse tumor (NC65), preliminary report. Invest Urol 16:106–112
Itoh K, Tilden AB and Balch CM (1985) Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. Cancer Res 45:3173–3178
Kato K, Yamada T, Kawahara K, Onda H, Asano T, Sugino H and Kakinuma A (1985) Purification and characterization of recombinant human interleukin-2 produced in Escherichia Coli. Biochem Biophys Res Commun 130:692–699
Lee SH, Aggarwal BB, Rinderknecht E, Assisi F and Chiu H (1984) The synergistic anti-proliferative effect of γ-interferon and human lymphotoxin. J Immunol 133:1083–1086
Mule JJ, Shu S, Schwarz SL and Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant interleukin-2. Science 225:1487–1489
Nakano E, Tada Y, Ichikawa Y, Fujioka H, Matsuda M, Takaha M and Sonoda T (1987) Lysis of autologous tumor cells by peripheral blood lymphocytes treated with interleukin 2 in patients with renal cell carcinoma. J Urol 137:641–648
Ochoa AC, Gromo G, Alter BJ, Sondel PM and Bach FH (1987) Long-term growth of lymphokine-activated killer(LAK)cells: role of anti-CD3, β-IL1, Interferon-γ, and-β. J Immunol 138:2728–2733
Roberts K and Lotze MT (1988) Interleukin 2 promotes conjugate formation by purified LAK precursors and T lymphocytes: evaluation of conjugates using flow cytometric techniques. J Biol Resp Modif 7:249–266
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Sjögren HO, Helström I, Bansal SC and Helström KE (1971) Suggestive evidence that the “blocking antibodies” of tumor bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci USA 68:1372–1375
Sugarbaker PH, Matthews W, Steller EP and Eggermont AMM (1987) Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells. J Biol Resp Modif 6:430–445
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr. and Shepard HM (1985) Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230:943–945
Talmadge JE and Herberman RB (1986) The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70:171–182
Uchida A and Micksche M (1983) Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions. Int J Cancer 32:37–44
Wanebo HJ, Riley T, Katz D, Pace RC, Jones ME and Cantrell RW (1988) Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. Cancer 61:462–474
About this article
Cite this article
Kanamaru, H., Yoshida, O. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay. Urol. Res. 17, 259–264 (1989). https://doi.org/10.1007/BF00262607
- LAK cells
- Renal cancer
- Serum suppressive factor
- Crystal violet assay